In rat models of T2DM, GLP-1RA treatment is associated with increases in the OPG/RANKL ratio, serum osteocalcin, and femoral BMD, stimulation of RUNX2 activity, and decreased expression of mRNA and serum levels of SOST/sclerostin [48]. The gene discussed is SOST; the disease is type 2 diabetes mellitus.